A lthough cell surface metalloendopeptidases degrade neuropeptides in the extracellular fl uid to terminate signaling, the function of peptidases in endosomes is unclear. We report that isoforms of endothelinconverting enzyme-1 (ECE-1a-d) are present in early endosomes, where they degrade neuropeptides and regulate post-endocytic sorting of receptors. Calcitonin gene-related peptide (CGRP) co-internalizes with calcitonin receptorlike receptor (CLR), receptor activity-modifying protein 1 (RAMP1), β-arrestin2, and ECE-1 to early endosomes, where ECE-1 degrades CGRP. CGRP degradation promotes CLR/RAMP1 recycling and β-arrestin2 redistribution to the cytosol. ECE-1 inhibition or knockdown traps CLR/ RAMP1 and β-arrestin2 in endosomes and inhibits CLR/ RAMP1 recycling and resensitization, whereas ECE-1 overexpression has the opposite effect. ECE-1 does not regulate either the resensitization of receptors for peptides that are not ECE-1 substrates (e.g., angiotensin II), or the recycling of the bradykinin B 2 receptor, which transiently interacts with β-arrestins. We propose a mechanism by which endosomal ECE-1 degrades neuropeptides in endosomes to disrupt the peptide/receptor/β-arrestin complex, freeing internalized receptors from β-arrestins and promoting recycling and resensitization.
Introduction
Membrane-associated metalloendopeptidases play a major role in the post-secretory processing of regulatory peptides. Cell surface peptidases cleave peptides in the extracellular fl uid to generate biologically active forms or inactivate mature peptides. For example, angiotensin-converting enzyme-1 converts angiotensin (AT) I to ATII, which activates the ATII type 1A receptor (AT 1A R), and degrades bradykinin (BK) to limit activation of the BK B 2 receptor (B 2 R) (Yang et al., 1970 (Yang et al., , 1971 . Neprilysin (NEP) degrades substance P (SP) to limit activation of the neurokinin-1 receptor (NK 1 R) and terminate neurogenic infl ammation (Okamoto et al., 1994; Lu et al., 1997; Sturiale et al., 1999) . Less is known about the role of intracellular membrane metalloendopeptidases.
Endothelin-converting enzyme 1 (ECE-1) is a metalloendopeptidase of plasma and endosomal membranes. Four ECE-1 isoforms (a-d) arise from a single gene using alternate promoters (Schmidt et al., 1994; Shimada et al., 1995; Schweizer et al., 1997; Valdenaire et al., 1999) . Whereas ECE-1 isoforms share a common catalytic domain, differences in the N-terminal domains specify variable subcellular distribution (Schweizer et al., 1997; Azarani et al., 1998; Brooks et al., 2000; Muller et al., 2003; Hunter and Turner, 2006) . ECE-1b and ECE-1d are mainly present in endosomal membranes (Schweizer et al., 1997; Azarani et al., 1998; Muller et al., 2003) , and ECE-1a and ECE-1c are mainly at the plasma membrane, with a minor localization in endosomes (Schweizer et al., 1997; Muller et al., 2003) . Cell surface ECE-1 converts big-endothelin (ET) to the pressor peptide ET-1 (Xu et al., 1994) , and inactivates BK (Hoang and Turner, 1997) . The function of ECE-1 in endosomes is not fully understood. However, ECE-1 can degrade neuropeptides such as SP, BK, ATI, and neurotensin at an acidic endosomal pH (Johnson et al., 1999; Fahnoe et al., 2000) . Because many peptides traffi c to endosomes with their receptors, we hypothesized that Using RT-PCR with isoform-specifi c primers, we amplifi ed mRNA encoding ECE-1a-d from HEK, SK-N-MC, and A549 cells, and confirmed identity by sequencing (Fig. S1 A, available at http://www.jcb.org/cgi/content/full/jcb.200704053/DC1). We amplifi ed transcripts of B 2 R in HEK cells, CLR and RAMP1 in SK-N-MC cells, and AT 1A R in A549 cells (Fig. S1 A) . We detected ECE-1 ‫021ف(‬ kD) in membranes from HEK, SK-N-MC, and A549 cells by Western blotting (antibody 473-17-A to all ECE-1 isoforms) (Fig. S1 B) . Thus, HEK, SK-N-MC and A549 cells express all ECE-1 isoforms.
ECE-1 isozymes are present in early endosomes
We examined the subcellular localization of ECE-1a-d-GFP expressed in HEK cells. All ECE-1 isoforms colocalized with early endosomal antigen 1 (EEA1) to varying extents. ECE-1b and ECE-1d prominently colocalized with EEA1 ( Fig. 1 A, arrows) . ECE-1a and ECE-1c were mainly at the plasma membrane ( Fig. 1 A, arrowheads) , but sometimes colocalized with EEA1 ( Fig. 1 A, arrows) . To confi rm the endosomal localization of ECE-1a-d, we coexpressed ECE-1a-d-GFP with Rab5aQ79L-CFP, a constitutively active mutant that causes endosomal fusion, facilitating detection of proteins in endosomes (Stenmark et al., 1994) . All isoforms of ECE-1 prominently colocalized with Rab5aQ79L in enlarged endosomes ( Fig. 1 B, arrows), although ECE-1a and ECE-1c were also detected at the plasma membrane ( Fig. 1 B, arrowheads) . Because overexpression may alter the subcellular distribution of ECE-1, we localized endogenous ECE-1 (antibody 52-6497). This antibody recognized ECE-1b and ECE-1d, but not ECE-1a or ECE-1c expressed in KNRK cells, and untransfected KNRK cells, which do not express ECE-1 mRNA, were unstained (unpublished data). In HEK, SK-N-MC, and A549, immunoreactive ECE-1b/d colocalized with EEA1 ( Fig. 1 , C-E; arrows). Staining of HEK cells was abolished by preabsorption with the ECE-1 fragment used for immunization ( Fig. 1 C, right) . Thus, endogenous ECE-1b/d are present in early endosomes.
CGRP and CLR traffi c from the plasma membrane to early endosomes containing ECE-1
To determine whether CGRP traffi cs to endosomes containing ECE-1, we incubated HEK-CLR-RAMP1 cells expressing ECE-1a-d-GFP with Alexa-CGRP (100 nM). After 1 h at 4°C, CGRP was at the plasma membrane, and ECE-1 isoforms were in endosomes or at the plasma membrane (Fig. 1 F) . After washing and 30 min incubation at 37°C, CGRP was prominently colocalized in endosomes with ECE-1b and ECE-1d ( Fig. 1 F,  arrows) . Some endosomes containing CGRP also contained ECE-1c and were in proximity to intracellular ECE-1a ( Fig. 1 F,  arrows) . CGRP was also prominently detected in early endosomes with endogenous immunoreactive ECE-1b/d and EEA1 in HEK-CLR-RAMP1 cells (Fig. 1 G, arrows) . In HEK-CLR-RAMP1 cells expressing ECE-1a-d-GFP, CGRP (100 nM, 30 min, 37°C) induced traffi cking of immunoreactive CLR to endosomes containing ECE-1b and ECE-1d ( Fig. S2 , arrows; available at http:// www.jcb.org/cgi/content/full/jcb.200704053/DC1). Although CLR was detected in endosomes in close proximity to intracellular ECE-1a and ECE-1c, colocalization was less apparent.
Thus, CGRP and CLR traffi c to early endosomes containing ECE-1 isoforms.
ECE-1 hydrolyzes CGRP, ATI, and BK, but not ATII, at endosomal pH
The pH optimum for ECE-1 is broad and substrate dependent (Johnson et al., 1999; Fahnoe et al., 2000) . Although ECE-1 converts big-ET to ET-1 at a neutral pH optimum (pH 6.8-7.0), consistent with generating ET-1 at the cell surface, ECE-1 hydrolyzes SP and ATI at an acidic pH optimum (pH 5.6-5.8), similar to that of endosomes. To determine if ECE-1 degrades CGRP at endosomal pH, we incubated CGRP with recombinant human (rh) ECE-1 at endosomal pH 5.5 (Pelkmans et al., 2004) . rhECE-1 degraded CGRP in a concentration-dependent manner (Fig. 2, A 
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-Pro 29 bonds. Because the biological activity of CGRP depends on the 8-37 sequence (Poyner et al., 1998) , this hydrolysis would inactivate CGRP. CGRP degradation was minimal at extracellular fl uid pH 7.4 (Fig. 2 B) . The ECE-1 inhibitor SM-19712 (Umekawa et al., 2000) (100 μM) abolished rhECE-1 degradation of CGRP at pH 5.5 (Fig. 2 B, Fig. S3 ). Because ATI is an ECE-1 substrate (Johnson et al., 1999) , we also examined hydrolysis of ATII. When ATII was incubated with 83 nM rhECE-1 at pH 5.5 or 7.4, there was no detectable degradation at up to 480 min (Fig. 2 C) , although rhECE-1 degraded ATI under the same conditions (Fig. 2 C) . BK is also degraded by ECE-1, but there are confl icting reports about the pH optimum (Hoang and Turner, 1997; Johnson et al., 1999; Fahnoe et al., 2000) . rhECE-1 (83 nM) degraded BK at pH 5.5 and 7.4, and SM-19712 prevented this degradation, but degradation was faster at pH 5.5 (Fig. 2 D) . Thus, ECE-1 degrades some (CGRP, ATI, BK) but not all (ATII) vasoactive peptides. The pH optimum favors degradation in acidifi ed endosomes and prevents degradation at the cell surface.
ECE-1 degrades endocytosed CGRP
To examine the contribution of ECE-1 to the degradation of endocytosed CGRP, we incubated HEK-CLR-RAMP1 cells with (unidentifi ed peptide) ( (Fig. 2 G) . Thus, ECE-1 degrades CGRP in endosomes, and endosomal acidifi cation is necessary for degradation.
ECE-1 inhibition and knockdown slows CLR and RAMP1 recycling
Acidotropic agents suppress recycling and resensitization of many GPCRs, including CLR/RAMP1 and NK 1 R (Grady et al., 1995; Garland et al., 1996; Cottrell et al., 2007) . We determined whether ECE-1, by degrading CGRP in acidifi ed endosomes, promotes dissociation of CGRP from CLR/RAMP1 to accelerate recycling. Cell surface receptors were labeled by incubating HEK-CLR-RAMP1 cells with antibodies to extracellular CLR (HA11) and RAMP1 (Myc) epitopes. Cells were exposed to CGRP (100 nM, 1 h, 37°C), washed, and recovered in CGRP-free medium. In unstimulated cells, CLR and RAMP1 colo calized at the plasma membrane (Fig. 3, A and B; arrowheads) . In vehicletreated cells (DMSO), CGRP caused internalization of CLR and RAMP1 into the same endosomes after 1 h (Fig. 3 A, arrows) . CLR and RAMP1 recycled from 2-6 h ( Fig. 3 A, arrowheads) . Fig. 3 B, arrows), but caused their retention in endosomes even at 6 h ( Fig.  3 B, arrows). To confi rm the role of ECE-1 in CLR recycling, we used siRNA to knockdown ECE-1. ECE-1 siRNA suppressed levels of ECE-1 detected by Western blotting by 71 ± 7% after 72 h, whereas control siRNA had a minimal effect (10 ± 6% reduction) compared with untransfected cells ( In unstimulated vehicle-treated cells, β-arrestin2 was cytosolic and CLR was at the plasma membrane. After 2 min with CGRP, β-arrestin2 was at the plasma membrane (arrowheads), and after 1 h β-arrestin2 and CLR colocalized in endosomes (arrows). After 1 h recovery, β-arrestin2 was mostly cytosolic and CLR remained in endosomes, and after 2-4 h β-arrestin2 was cytosolic and CLR was at the plasma membrane. ECE-1 siRNA also down-regulated ECE-1 detected by immunofl uorescence (Fig. 3 C) . In cells transfected with control siRNA, CGRP induced CLR endocytosis and recycling (Fig. 3 C) . In cells transfected with ECE-1 siRNA, CLR was retained in endosomes after 6 h. Quantifi cation of CLR at the plasma membrane after 6 h revealed that SM-19712 and ECE-1 siRNA inhibited recycling of CLR by >50% (Fig. 3 D) . Thus, active ECE-1 is necessary for CLR and RAMP1 recycling.
SM-19712 did not affect endocytosis of CLR/RAMP1 (

Inhibition of ECE-1 and endosomal acidifi cation prolongs the interaction between -arrestin2 and CLR
We similarly determined if ECE-1 is necessary for the dissociation of CLR and β-arrestins in endosomes of HEK-CLR-RAMP1 cells expressing β-arrestin2-GFP. In unstimulated cells, β-arrestin2 was cytosolic and CLR was at the plasma membrane (Fig. 4 , A and B). In vehicle-treated cells, CGRP induced the translocation of β-arrestin2 to the plasma membrane after 2 min (Fig. 4 A, arrowheads) and caused endocytosis of CLR and β-arrestin2 into the same endosomes after 1 h (Fig. 4 A, arrows). After 1 h recovery, β-arrestin2 had returned to the cytosol and CLR was in endosomes. After 2-4 h, CLR was at the plasma membrane. SM-19712 did not affect CGRP-induced membrane translocation of β-arrestin2 or internalization of CLR and β-arrestin2, but caused their retention in endosomes (Fig. 4 B, arrows) . The colocalization coeffi cient of CLR and β-arrestin2 at 4 h was approximately threefold higher in cells treated with SM-19712 compared with controls (Fig. 4 C) . Thus, ECE-1 is necessary for the dissociation of β-arrestins from the receptor in endosomes, and the return of β-arrestins to the cytosol.
To examine the role of endosomal acidifi cation in the traffi cking of CLR, RAMP1, and β-arrestin2, we treated cells with bafi lomycin A 1 . In vehicle-treated cells, CGRP induced traffi cking of CLR, RAMP1, and β-arrestin2 into the same endosomes after 1 h ( Fig. 5 A, arrows) . At 1 h recovery, CLR and RAMP1 remained in endosomes, and β-arrestin2 was cytosolic, and at 4 h CLR and RAMP1 were at the plasma membrane (Fig. 5 A) . Bafi lomycin A 1 did not affect CGRP-induced traffi cking of CLR, RAMP1, and β-arrestin2 to endosomes (Fig. 5 B, arrows) , but caused retention of CLR, RAMP1, and β-arrestin2 in endosomes for up to 4 h recovery (Fig. 5 B, arrows) . The colocalization coeffi cient of CLR and β-arrestin2 at 4 h was more than twofold higher in cells treated with bafi lomycin A 1 compared with control cells (Fig. 5 C) . Thus, endosomal acidifi cation is necessary for the redistribution of β-arrestin2 to the cytosol and for CLR and RAMP1 recycling.
Acidifi cation promotes the dissociation of CGRP from CLR/RAMP1
By inducing the dissociation of CGRP from CLR and RAMP1, endosomal acidifi cation may promote recycling and resensitization of CLR and RAMP1 and the return of β-arrestin2 to the cytosol. Therefore, we examined binding of 125 I-CGRP to membranes from HEK-CLR-RAMP1 in buffers of graded pH (7.5-5.0). Although binding was similar from pH 7.5 to pH 6.5, it sharply declined at pH <6.5, with a >30% reduction at pH 6.0 and a >75% reduction at pH 5.5 (Fig. 5 D) . At endosomal pH 5.5, ‫%02ف‬ of CGRP was bound to CLR/RAMP1. By degrading CGRP in endosomes to forms that are unable to rebind CLR/ RAMP1, ECE-1 may promote the further dissociation of CGRP from CLR/RAMP1.
Endosomal ECE-1 regulates resensitization of CGRP signaling
To determine if ECE-1-induced recycling of CLR/RAMP1 mediates resensitization, we examined the effect of ECE-1 inhibition, knockdown, or overexpression on resensitization of CGRPinduced Ca 2+ signaling. HEK-CLR-RAMP1 cells were preincubated with CGRP (100 nM, 1 h, 37°C) or vehicle (control), washed, and recovered in CGRP-free medium for 0-6 h. The change in [Ca 2+ ] i to a second CGRP challenge (30 nM) was measured. Preincubation with CGRP abolished CGRP-induced Ca 2+ signals at 0 h recovery, indicating complete desensitization (Fig. S5 A, available at http://www.jcb.org/cgi/content/full/jcb.200704053/DC1). In cells with active ECE-1, responses to CGRP fully resensitized at 4-6 h recovery (Fig. 6 A) . SM-19712 did not affect desensitization but strongly inhibited resensitization at all times (Fig. 6 A) . We obtained similar results in SK-N-MC cells. Preincubation with CGRP (100 nM, 1 h, 37°C) completely desensitized responses to CGRP challenge (100 nM) (Fig. S5 B) . After 4 h recovery, responses to CGRP were resensitized by 54 ± 5% (Fig. 6 B) . SM-19712 did not affect desensitization, but strongly inhibited resensitization at 4 h (33% inhibition; Fig. 6 B) . We used ECE-1 siRNA to confi rm the role of ECE-1 in regulating resensitization in HEK-CLR-RAMP1 cells. In cells treated with control siRNA, after 1 h exposure to CGRP (100 nM) and 2 h recovery, CGRP (30 nM)-induced Ca 2+ signaling was resensitized by 82 ± 5% (Fig. 6 C) . ECE-1 siRNA strongly inhibited resensitization at 2 h (>35% inhibition, Fig. 6 C) .
Conversely, we determined whether ECE-1 overexpression accelerated resensitization of CGRP-induced Ca 2+ signaling. In HEK cells expressing CLR/RAMP1 alone (control), CGRPinduced Ca 2+ signaling was resensitized by 33 ± 2% after 2 h (Fig. 6 D) . Overexpression of ECE-1a-d accelerated resensitization of CGRP-induced Ca 2+ signaling (Fig. 6 D) . The most pronounced effect was in cells overexpressing ECE-1c, where there was 75 ± 5% resensitization at 2 h.
To determine if ECE-1 degrades CGRP at the cell surface to attenuate signaling, we examined the effects of ECE-1 inhibition on responses to a single challenge with CGRP. HEK-CLR-RAMP1 or SK-N-MC cells were treated with vehicle or SM-19712 and then challenged with CGRP (30 nM for HEK-CLR-RAMP1, 100 nM for SK-N-MC). SM-19712 did not affect magnitude or duration of CGRP-induced increases in [Ca 2+ ] i in HEK-CLR-RAMP1 cells (Fig. 6 F) or SK-N-MC cells (Fig. 6 F) . ECE-1 siRNA did not affect the response to an initial challenge with CGRP (unpublished data). Thus, ECE-1 is a major determinant of CLR/RAMP1 resensitization.
ECE-1 isoforms co-internalize with CGRP
Although ECE-1c was mainly at the cell surface, overexpression of ECE-1c had the largest effect on resensitization of CGRPinduced Ca 2+ signaling. The observation that overexpression of Rab5aQ79L caused a pronounced localization of ECE-1c in endosomes suggests that this isoform constitutively internalizes, becoming trapped in enlarged endosomes. To examine traffi cking of ECE-1 from the plasma membrane, we incubated HEK cells expressing ECE-1a-d-HSV with FITC-labeled antibody to the extracellular HSV epitope. When incubated with HSV antibody for 1 h at 4°C, ECE-1a-d-HSV were detected at the plasma membrane (Fig. 7 A, arrowheads) . At 30 min after washing and warming to 37°C, all isoforms were prominently detected in endosomes (Fig. 7 A, arrows) . By expressing ECE-1a-d-HSV in HEK-CLR-RAMP1 cells, we determined whether ECE-1a-d-HSV co-internalize with Alexa-CGRP. After incubation with HSV antibody and Alexa-CGRP at 4°C, ECE-1a-d-HSV colocalized with CGRP at the plasma membrane (Fig. 7 B, arrowheads) . After 30 min at 37°C, ECE-1a-d-HSV colocalized with CGRP in endosomes (Fig. 7 C, arrows) . Thus, ECE-1 isoforms constitutively internalize and traffi c with CGRP and CLR/RAMP1 to the same endosomes.
To determine whether CGRP promoted endocytosis of ECE-1, we used fl ow cytometry to quantify ECE-1c-HSV at the cell surface of HEK-CLR-RAMP1 cells. In cells incubated with vehicle for 30 min at 37°C, ECE-1c-HSV at the cell surface was 55.9 ± 5.0% of that at 4°C (100%), consistent with constitutive endocytosis (Fig. 7 D) . CGRP (100 nM, 30 min, 37°C) did not affect this endocytosis. Thus, activation of CLR/RAMP1 with CGRP does not promote ECE-1c endocytosis.
We used immunoprecipitation and Western blotting to determine whether CLR interacts with ECE-1c. HEK-CLR-RAMP1 cells expressing ECE-1c-HSV or empty vector were incubated with CGRP (100 nM, 0-30 min, 37°C). ECE-1c was immunoprecipitated and blots were probed for ECE-1c and CLR.
Although ECE-1c was successfully immunoprecipitated and detected by Western blotting, CLR was not detectable in the immunoprecipitates before or after treatment with CGRP (Fig. 7 E) . There were no signals in cells expressing vector control. Thus, ECE-1c and CLR do not detectably associate. To investigate the selectivity with which ECE-1 controls receptor recycling and resensitization, we examined resensitization of the class B AT 1A R. HEK-AT 1A R cells were preincubated with ATII (100 nM, 1 h, 37°C) to desensitize AT 1A R or vehicle (control), washed, recovered for 20 min or 2 h, and challenged with ATII (100 nM). In cells with active ECE-1, ATII-induced Ca 2+ signaling was resensitized to 59 ± 3% at 20 min (Fig. 8 A) and 96 ± 3% at 2 h (unpublished data). SM-19712 did not affect resensitization at either time. SM-19712 also did not affect resensitization of responses to ATII in A549 cells expressing endogenous AT 1A R and ECE-1 (Fig. 8 B) . Thus, ECE-1 does not regulate resensitization of AT 1A R, consistent with its inability to degrade ATII at endosomal pH.
We examined the role of ECE-1 and endosomal acidifi cation in regulating resensitization of the class A B 2 R. HEK cells, which naturally express B 2 R and ECE-1, were preincubated with BK (100 nM, 10 min, 37°C) or vehicle (control), washed, and challenged with BK (100 nM) after a 0-120-min recovery. Preincubation with BK abolished BK-induced Ca 2+ signals at 0 min recovery, indicating complete desensitization (Fig. S5 C) . BK-induced Ca 2+ signaling rapidly resensitized to 45 ± 2% at 10 min and 87 ± 6% at 120 min recovery (Fig. 8 C) . SM-19712 or bafi lomycin A 1 had no effect on desensitization (Fig. S5 C) or resensitization (Fig. 8 C) . Thus, although ECE-1 rapidly degrades BK at endosomal pH, ECE-1 and endosomal acidifi cation do not affect B 2 R resensitization. Moreover, neither SM-19712, thiorphan (NEP inhibitor), nor phosphoramidon (NEP and ECE-1 inhibitor) affected responses to a single BK (100 nM) challenge of HEK cells (Fig. 8 D) . Thus, cell surface ECE-1 and NEP do not regulate BK-induced activation of the B 2 R in HEK cells.
One explanation of the lack of involvement of ECE-1 in B 2 R resensitization is that B 2 R recycles without traffi cking to ECE-1-containing endosomes. To examine this possibility, we incubated HEK cells expressing ECE-1a-d-HSV with Alexa-kallidin (100 nM, BK with N-terminal Lys labeled with Alexa), an agonist of the B 2 R, and localized HSV-FITC and Alexa-kallidin. After 1 h at 4°C, kallidin and ECE-1a-d-HSV colocalized to the plasma membrane (unpublished data). After 10 min at 37°C, kallidin prominently colocalized with ECE-1a-d-HSV in endosomes ( Fig. 9 A for ECE-1b) . Kallidin also internalized to localize with endogenous immunoreactive ECE-1 in HEK cells (unpublished data). Thus, kallidin and presumably BK and B 2 R traffi c to endosomes containing ECE-1a-d.
Alternatively, because B 2 R interacts only transiently with β-arrestins (Simaan et al., 2005) , B 2 R may rapidly dissociate from β-arrestins to recycle by a mechanism that does not require ECE-1 degradation of BK. To assess this possibility, HEK-B 2 R cells expressing β-arrestin2-GFP were incubated with antibody to the extracellular B 2 R HA11 epitope, and then stimulated with BK (100 nM, 10 min). After 10 min, B 2 R and β-arrestin2 colocalized in endosomes, and after 60 min recovery B 2 R had recycled and β-arrestin2 was cytosolic (Fig. 9 B) . SM-19712 did not affect this traffi cking (Fig. 9 C) . Substitution of the C terminus of the B 2 R with that of the class B V 2 R generates a functional receptor (B 2 R-V 2 RCT) that shows sustained interactions with β-arrestins (Simaan et al., 2005) . BK induced sustained colocalization of B 2 R-V 2 RCT and β-arrestin2 in endosomes, and B 2 R-V 2 RCT recycled more slowly (2 h) than B 2 R (1 h) (Fig. 9 D) . SM-19712 inhibited recycling of B 2 R-V 2 RCT, causing it retention in endosomes with β-arrestin2 (Fig. 9 E) . Quantitative analysis confi rmed that SM-19712 inhibited recycling of B 2 R-V 2 RCT (>50% reduction) but not B 2 R (<10% reduction) (Fig. 9 F) , and caused a twofold increase in the colocalization coeffi cient of B 2 R-V 2 RCT with β-arrestin2 (Fig. 9 G) . Thus, ECE-1 does not control B 2 R recycling because this receptor interacts transiently with β-arrestins.
Discussion
We have defi ned a novel role for endosomal ECE-1 in the postendocytic sorting of GPCRs and β-arrestins. Our results show that CGRP, CLR, RAMP1, β-arrestins, and ECE-1 traffi c to early endosomes (Fig. 10, steps 1-4) . ECE-1 degrades CGRP in acidifi ed endosomes to fragments that are unable to rebind CLR/ RAMP1. This degradation promotes the dissociation of CGRP and β-arrestins from CLR/RAMP1, inducing redistribution of β-arrestins to the cytosol and recycling and resensitization of CLR/RAMP1. This mechanism is specifi c, because ECE-1 does not degrade ATII and thus does not regulate recycling or resensitization of the AT 1A R. Moreover, ECE-1 has little effect on resensitization of the rapidly recycling B 2 R that interacts only transiently with β-arrestins.
ECE-1 shows isoform-specifi c localization in early endosomes containing CGRP, CLR,
RAMP1, and -arrestins
ECE-1b and ECE-1d were prominently detected in EEA1-positive endosomes. Although ECE-1a and ECE-1c were mainly at the plasma membrane, they also colocalized with EEA1. All ECE-1 isoforms, including ECE-1a and ECE-1c, were prominently detected in enlarged endosomes expressing the constitutively active In unstimulated vehicle-treated cells, β-arrestin2 was cytosolic (arrows) and B 2 R and B 2 R-V 2 RCT were at the plasma membrane (arrowheads). After 10 min with BK, β-arrestin2 colocalized in endosomes with B 2 R and B 2 R-V 2 RCT (arrows). After 1 h (B 2 R) or 2 h (B 2 R-V 2 RCT) recovery, β-arrestin2 was cytosolic and B 2 R and B 2 R-V 2 RCT were at the plasma membrane. (C and E) SM-19712 did not affect traffi cking of B 2 R or β-arrestin2 (C), but caused retention of β-arrestin2 and B 2 R-V 2 RCT in endosomes (E) (arrows). Bar, 10 μm. (F) Quantifi cation of the effect of SM-19712 on recycling of B 2 R at 1 h recovery and B 2 R-V 2 RCT at 2 h recovery. SM-19712 caused an ‫%05ف‬ reduction in B 2 R-V 2 RCT recycling. (G) Colocalization coeffi cient of β-arrestin2 and B 2 R at 1 h recovery and B 2 R-V 2 RCT at 2 h recovery. SM-19712 did not affect colocalization with B 2 R but caused an approximately twofold increase in colocalization with B 2 R-V 2 RCT. *, P < 0.05.
Rab5aQ79L
, which stimulates homotypic early endosome fusion (Stenmark et al., 1994) . These results are consistent with reports of the presence of ECE-1b in early, recycling, and late endosomes, ECE-1d in recycling endosomes, and ECE-1a and ECE-1c at the plasma membrane (Schweizer et al., 1997; Azarani et al., 1998; Muller et al., 2003) .
CGRP, CLR, and RAMP traffi cked to endosomes containing ECE-1. Because CLR/RAMP1 and β-arrestin2 prominently colocalized in endosomes, β-arrestin2 also colocalizes with ECE-1 in endosomes. CGRP and CLR most prominently colocalized with ECE-1b and ECE-1d, and there was limited colocalization with ECE-1a and ECE-1c in endosomes. By labeling ECE-1 at the cell surface with antibody to an extracellular epitope, we observed constitutive endocytosis of all ECE-1 isoforms. Although we cannot exclude the possibility that antibody binding caused ECE-1 endocytosis, the prominent localization of ECE-1a and ECE-1c in Rab5aQ79QL-containing endosomes supports the suggestion of dynamic regulation of these isozymes. Indeed, ECE-1c, and to a lesser extent ECE-1b and ECE-1d, constitutively internalize by a dynamin-dependent mechanism and recycle (Muller et al., 2003) . Notably, all ECE-1 isoforms co-internalized with Alexa-CGRP. Although flow cytometry indicated that CGRP did not affect endocytosis of ECE-1c, the possibility that CGRP induces traffi cking of ECE-1 from the plasma membrane to endosomes requires further evaluation because the subcellular distribution of ECE-1 is regulated by second messenger kinases (Jafri and Ergul, 2006 ). Thus, receptor-activated second messenger kinases may stimulate the redistribution of ECE-1 isoforms to endosomes, promoting neuropeptide degradation.
ECE-1 degrades CGRP in acidifi ed early endosomes
ECE-1 hydrolyzed six bonds within the biologically active C-region of CGRP (8-37), which would inactivate the peptide. ECE-1 degraded CGRP at pH 5.5 but not at pH 7.4, in accord with the narrow acidic pH optimum reported for ECE-1 degradation of other neuropeptides (Fahnoe et al., 2000) . The lack of degradation at pH 7.4 suggests that ECE-1 present at the plasma membrane is unlikely to degrade CGRP in the extracellular fluid to regulate activation of CLR/RAMP1. Indeed, ECE-1 inhibition/knockdown did not affect CGRP-induced Ca 2+ signaling in HEK or SK-N-MC cells, which expressed ECE-1a and ECE-1c that are known to be at the cell surface. The inability of ECE-1 to degrade CGRP and SP in the extracellular fl uid contrasts with NEP, which degrades SP at the cell surface to limit activation of the NK 1 R (Okamoto et al., 1994) (Fig. 10, step 5) .
The observation that SM-19712 prevented degradation of internalized CGRP in HEK-CLR-RAMP1 cells indicates that ECE-1 degrades CGRP in endosomes. The isoform of ECE-1 that is mainly responsible for the degradation of endocytosed CGRP remains to be identifi ed because all isoforms prominently colocalized with Alexa-CGRP. The vacuolar H + -ATPase inhibitor bafilomycin A 1 also prevented degradation of endocytosed CGRP, indicating a requirement for endosomal acidifi cation. Endosomal acidifi cation may promote CGRP degradation by enhancing ECE-1 activity or by causing CGRP dissociation from CLR/RAMP1. ECE-1 probably degrades receptor-dissociated CGRP, but it remains to be determined whether ECE-1 degrades receptor-associated peptide. Although we did not detect interaction of ECE-1c with CLR/RAMP1, another metalloendopeptidase, endopeptidase 3.4.24.15, interacts with the C-tails of the AT 1A R and B 2 R (Shivakumar et al., 2005) . Although principally cytosolic, endopeptidase 24.15 has been detected in endosomes and degrades BK (Norman et al., 2003) . Cathepsin B degrades EGF and insulin-like growth factor-I in endosomes (Authier et al., 1999 (Authier et al., , 2005 . Thus, several proteases may degrade peptides in endosomes. Several observations suggest that ECE-1 promotes dissociation of GPCRs from β-arrestins in endosomes, thereby allowing receptors to recycle. First, ECE-1 inhibition/knockdown prevented CLR/RAMP1 recycling from endosomes. Second, ECE-1 inhibition prevented the translocation of β-arrestin from endosomes to the cytosol. Third, inhibition of vacuolar H + -ATPase prevented CLR/RAMP1 recycling and the return of β-arrestin to the cytosol. Thus, although we did not directly examine the interactions between CLR/RAMP and β-arrestins, our data suggest that ECE-1, by degrading CGRP in acidifi ed endosomes, promotes dissociation of β-arrestins from CLR/RAMP1, accelerating the return of β-arrestins to the cytosol and of CLR/RAMP1 to the cell surface. ECE-1-induced dissociation of β-arrestins from CLR/RAMP1 may promote the dephosphorylation of CLR by endosomal phosphatases, permitting recycled receptors to resensitize (Fig. 10, step 3) .
Our results suggest that ECE-1 accelerates resensitization of CGRP signaling. In HEK-CLR-RAMP1 and SK-N-MC cells, ECE-1 inhibition and knockdown markedly delayed resensitization of CGRP signaling. Thus, the mechanism is not unique to cells overexpressing ECE-1, CLR, and RAMP1, but also occurs in cells that endogenously express these proteins, and inhibition of existing ECE-1 and suppression of ECE-1 synthesis have similar effects. Conversely, overexpression of all ECE-1 isoforms in HEK-CLR-RAMP1 cells markedly amplifi ed resensitization of CGRP signaling. Although Alexa-CGRP colocalized most prominently with ECE-1b and ECE-1d in endosomes, overexpression of ECE-1c had the greatest effect on resensitization. A likely explanation of this discrepancy is that CGRP prominently co-internalizes with ECE-1c, which constitutively internalizes and presumably recycles.
β-arrestins recruit components of the MAPK pathway, including src and raf-1, to endosomes, allowing endocytosed receptors to continue to signal (DeFea et al., 2000a,b; Tohgo et al., 2003) . ECE-1, by controlling the subcellular distribution of β-arrestins, may thereby affect mitogenic signaling of receptors, a possibility that requires further investigation. In support of this possibility, inhibitors of cathepsin B, which degrades insulin-like growth factor-I in endosomes, markedly infl uence insulin-like growth factor-I signaling (Navab et al., 2001) .
Specifi city of regulation of post-endocytic traffi cking and signaling of GPCRs by endosomal ECE-1 ECE-1 is expressed by endothelial, epithelial, smooth muscle, and neuronal cells, which are regulated by neuropeptides that are potential ECE-1 substrates Turner, 1997, 1999; Korth et al., 1999) . Endosomal ECE-1 may regulate receptors in these cells provided the peptide and its receptor traffi c to ECE-1-containing endosomes, and the peptide is an ECE-1 substrate at endosomal pH. Our fi nding that ECE-1 regulates recycling and resensitization of CLR/RAMP1 supports the report that ECE-1 also degrades tachykinins in endosomes to control recycling and resensitization of the NK 1 R . ECE-1 may also control post-endocytic traffi cking of the neurotensin 1 receptor because ECE-1 degrades neurotensin at acidic pH (Johnson et al., 1999) . CLR/RAMP1, NK 1 R, and neurotensin receptor 1 are class B GPCRs that colocalize for prolonged periods with β-arrestins in endosomes containing ECE-1 (Oakley et al., 1999 (Oakley et al., , 2000 (Oakley et al., , 2001 Hilairet et al., 2001; Schmidlin et al., 2003) . AT 1A R is also a class B GPCR that slowly recycles after activation by ATII. However, ECE-1 did not degrade ATII and ECE-1 inhibition did not affect resensitization of ATIIinduced Ca 2+ signaling. Thus, ECE-1 does not regulate all class B GPCRs, and further studies are required to determine whether this is a general mechanism.
Although ECE-1 rapidly degraded BK at pH 5.5 and the B 2 R agonist kallidin traffi cked to ECE-1-containing endosomes, SM-19712 did not affect B 2 R recycling or resensitization. An explanation for this discrepancy is that B 2 R is a class A GPCR that interacts with low affi nity with β-arrestins and rapidly recycles without a requirement for endosomal acidifi cation or BK degradation. Indeed, bafi lomycin A 1 did not affect resensitization of the B 2 R. Moreover, SM-19712 strongly inhibited recycling of B 2 R-V 2 RCT, which shows sustained interactions with β-arrestins (Simaan et al., 2005) . Thus, the lack of effect of an ECE-1 inhibitor on B 2 R recycling and resensitization signaling may be due to its low affi nity interactions with β-arrestins. Whether ECE-1 regulates traffi cking and signaling of class A GPCRs is unknown.
In summary, we have identifi ed a new role for endosomal ECE-1. ECE-1 co-internalizes with and degrades neuropeptides in acidifi ed endosomes. By degrading peptides to fragments that are unable to rebind receptors, ECE-1 destabilizes the peptide/ receptor/β-arrestin complex, and thereby initiates receptor recycling and resensitization. The mechanism requires that peptides are substrates for ECE-1 in acidifi ed endosomes, and that receptors show sustained interactions with β-arrestins which are disrupted by endosomal acidifi cation and peptide degradation. The observation that ECE-1 inhibitors prevent resensitization of responses to CGRP and SP, mediators of infl ammation and pain, suggests that inhibitors of endosomal ECE-1, by attenuating receptor resensitization, may provide a novel therapy for peptide-mediated diseases. ] i was measured in cells on glass coverslips or in suspension at 37°C using Fura-2AM as described Roosterman et al., 2007) . To examine responses to a single stimulus, cells were challenged with CGRP or BK (30 or 100 nM). To assess desensitization and resensitization, cells were incubated with CGRP, ATII, or BK (100-1,000 nM, 1 h, 37°C) or vehicle (control), washed, and recovered in agonist-free medium for 20 min to 6 h at 37°C. Cells were challenged with CGRP, ATII, or BK (30-1,000 nM), and [Ca 2+ ] i was measured. SM-19712 (10 μM) , phosphoramidon (1 μM), thiorphan (1 μM), bafi lomycin A 1 (0.15 or 1 μM), or vehicle (DMSO, control) was preincubated with cells for 20-60 min, and included in buffers throughout the experiment. siRNA siRNA reagents were from Dharmacon. ON-TARGET plus SMART pool (-005857-00) consisted of four distinct siRNA duplexes targeted to knockdown of human ECE-1 mRNA. siCONTROL Non-Targeting siRNA pool (D-001206) consisted of four off-target siRNA duplexes. HEK-CLR-RAMP1 cells (0.5 × 10 6 cells per well of 6-well plate in antibiotic-free medium) were transfected with 200 pmol siRNA and 5 μl of DharmaFECT 1 according to the manufacturer's instructions. Cells were incubated in the transfection medium for 72 h, and then used for experiments.
Materials and methods
Drug treatments
Flow cytometry
HEK-CLR-RAMP1 cells expressing ECE-1c-HSV were incubated with goat anti-HSV (1 mg/ml, 1 h, 4°C). Cells were washed, stimulated with CGRP (100 nM, 30 min, 37°C), and incubated with donkey anti-goat-FITC (1:200, 1 h, 4°C). Cells were analyzed using a FACSort (Becton Dickinson) and CELLQuest 3.3 software (BD Biosciences). Background fl uorescence was measured in cells treated with secondary antibody only and was subtracted from the fl uorescence histograms of the treatment groups.
Statistics
Results are expressed as mean ± SE from n ≥ 3 experiments. Results are compared by t test for two comparisons or ANOVA and Student-NewmanKuel's test for multiple comparisons, with P < 0.05 considered signifi cant. Representative images of cells and gels are shown from n ≥ 3 experiments. Fig. S1 shows endogenous expression of ECE-1a-d, B 2 R, CLR, RAMP1, and AT 1A R in HEK, SK-N-MC, and A549 cell lines. Fig. S2 shows that CGRP induces traffi cking of CLR to endosomes containing ECE-1. The chromatograms in Fig. S3 show that rhECE-1 degrades CGRP, and that endogenous ECE-1 degrades endocytosed 125 I-His 8 -CGRP in HEK cells. Fig. S4 shows that ECE-1 siRNA effectively suppresses levels of ECE-1 in HEK cells. 
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